LY01005, a GnRH agonist currently in clinical trials, aims to reduce estrogen levels [36], while Everolimus, an mTOR inhibitor, exerts anti-breast cancer effects through inhibition of the PI3K/Akt/mTOR pathway and activation of caspase-8-mediated apoptosis [37,38]. Here, MTOR is linked to breast carcinoma.